Concomitant use of risankizumab in moderate-to-severe psoriasis induced by ofatumumab in a patient with relapsing-remitting multiple sclerosis. // Medicina Clínica (English Edition). – URL: https://www.sciencedirect.com/science/article/pii/S2387020626003608?dgcid=rss_sd_all
Concomitant use of risankizumab in moderate-to-severe psoriasis induced by ofatumumab in a patient with relapsing-remitting multiple sclerosis. Medicina Clínica (English Edition). https://www.sciencedirect.com/science/article/pii/S2387020626003608?dgcid=rss_sd_all
“Concomitant use of risankizumab in moderate-to-severe psoriasis induced by ofatumumab in a patient with relapsing-remitting multiple sclerosis.” Medicina Clínica (English Edition).
@article{article117384,
title = {Concomitant use of risankizumab in moderate-to-severe psoriasis induced by ofatumumab in a patient with relapsing-remitting multiple sclerosis},
journal = {Medicina Clínica (English Edition)},
url = {https://www.sciencedirect.com/science/article/pii/S2387020626003608?dgcid=rss_sd_all}
}
Publication date: November–December 2026 Source: Acta Otorrinolaringologica (English Edition), Volume 77, Issue 6 Author(s): Daniel Álvarez de Castro, Sandra Pérez de la Iglesia, Miguel Ramírez Verdyguer, Francisco José Manzano Gómez